Market Cap (In USD)
4.42 Million
Revenue (In USD)
686 Thousand
Net Income (In USD)
-11.28 Million
Avg. Volume
6.29 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.3803-68.4
- PE
- -
- EPS
- -71.1
- Beta Value
- 0.0
- ISIN
- US05479L1044
- CUSIP
- 05479L104
- CIK
- 1701478
- Shares
- 14979354.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Francisco D. Salva
- Employee Count
- -
- Website
- https://azitrainc.com
- Ipo Date
- 2023-06-20
- Details
- Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
More Stocks
-
603156
-
ELFORGEEL FORGE LTD.
ELFORGE
-
ATUSF
-
605378
-
605218Ways Electron Co.,Ltd.
605218
-
SSCFFSmartcool Systems Inc.
SSCFF
-
0J2O
-
AHEXYAdecco Group AG
AHEXY